Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review
| Autor: | Saad Ullah Malik, Saher Nasir Amin, David Sharon, Muhammad Sardar, Raza Naseer, Qistas Ahmad, Patrick Lee, Muhammad Abuzar, Chaudhry Saad Sohail, Ali McBride, Ahmed Safdar, Muhammad Idrees, Rajshekhar Chakraborty, Faiz Anwer, Ali Younas Khan |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Bendamustine medicine.medical_specialty Efficacy Chronic lymphocytic leukemia Phases of clinical research Review Bruton tyrosine kinase inhibitor 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Chemoimmunotherapy Internal medicine Medicine Progression-free survival Relapse business.industry Ibrutinib BTK inhibitor PCI-32765 medicine.disease Regimen chemistry 030220 oncology & carcinogenesis Rituximab business 030215 immunology medicine.drug |
| Zdroj: | Journal of Hematology |
| ISSN: | 1927-1220 1927-1212 |
| DOI: | 10.14740/jh482 |
| Popis: | Ibrutinib has shown to have better efficacy than standard chemoimmunotherapy in del17 positive chronic lymphocytic leukemia (CLL) patients; however its role in del17 negative patients is less clear. We aim to evaluate the efficacy of ibrutinib-based regimens in CLL. Seven databases were searched in accordance with PRISMA statement guidelines using the following keywords: chronic lymphocytic leukemia, CLL, Bruton tyrosine kinase inhibitor, BTK inhibitor, ibrutinib, and PCI-32765. Data from only prospective clinical trials was included. In a phase 3 trial (n = 136), the overall response rate (ORR) with ibrutinib was 92% whereas 18% patients had a complete response (CR). Progression free survival (PFS) and overall survival (OS) at 2 years were 89% and 95% respectively. Phase 3 trial (n = 195) with single agent ibrutinib showed ORR of 63%. PFS at 6 months and OS at 12 months were 88% and 90% respectively. In a phase 2 trial of relapsed and/or refractory (R/R) or high risk treatment naive (TN) patients, combination of ibrutinib and rituximab (n = 104) achieved an ORR of 100% (CR 28%) as compared to ORR 98% (CR 21%) with ibrutinib monotherapy (n = 102) with no significant difference in PFS. Combination of ibrutinib and ublituximab (n = 64) had an ORR of 78% (CR 7%) in a phase 3 study. In del17p negative R/R patients, combination of bendamustine/rituximab (BR) and ibrutinib (n = 289) achieved an ORR of 83% (CR/CRi 10%) and the 18 month PFS was 79%. In a phase 2 trial treated with ibrutinib (n = 145), patients with del17p R/R disease achieved an ORR of 64% and the 24 month PFS and OS was 63% and 75% respectively. In TN del17p patients (n = 35), ORR was 97% (CR-0) and the 24 month PFS and OS were 82% and 84% respectively with single agent ibrutinib. Ibrutinib is the treatment of choice for patients with del17p mutation and has good efficacy in RR/TN patients without del17p mutation. Ibrutinib is being evaluated in combination with rituximab for del17p mutations. Future prospects include combination of ibrutinib with frontline chemotherapy and other novel agents for TN and RR del17p negative patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|